The latest FDA approval was based on the results of the ADVANCE trial, which showed that five times as many adults with mild to moderate plaque psoriasis receiving oral Otezla 30 mg twice daily ...

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Amgen maintains that Otezla remains the only approved oral systemic therapy with a broad indication and is “well positioned” to help the 4 million US patients with mild to moderate psoriasis ...

For many people with mild psoriasis ... Some prescription oral medications to manage psoriasis include Rheumatrex (methotrexate), Otezla (apremilast), Soriatane (acitretin), and Sotyktu ...

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque psoriasis, Artax Biopharma announced in a press release.